Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Canadian Cancer Trials Group
Dana-Farber Cancer Institute
SWOG Cancer Research Network
Hoosier Cancer Research Network
Eastern Cooperative Oncology Group
University of Minnesota
Association Européenne de Recherche en Oncologie